A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

Also called NCT07662213

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,200 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07662213
  • EU CT 2025-523933-24-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Germany, Hungary, Italy, Japan, Poland, South Korea, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07662213. Randomized; no masking; primary purpose treatment. Start 2026-07-06 (actual); primary completion 2028-05-23 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
Acronym
Eluminate-2
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Elecoglipron
Intervention (Drug)
Semaglutide
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07662213
Content hash
29cd1cb63340f6dcbe9213de779c0f932152cc5ed67b471ad876d4e320cb1a14